These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 15054402)

  • 1. Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients.
    Fogli A; Schiffmann R; Hugendubler L; Combes P; Bertini E; Rodriguez D; Kimball SR; Boespflug-Tanguy O
    Eur J Hum Genet; 2004 Jul; 12(7):561-6. PubMed ID: 15054402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The large spectrum of eIF2B-related diseases.
    Fogli A; Boespflug-Tanguy O
    Biochem Soc Trans; 2006 Feb; 34(Pt 1):22-9. PubMed ID: 16246171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eukaryotic initiation factor 2B (eIF2B) GEF activity as a diagnostic tool for EIF2B-related disorders.
    Horzinski L; Huyghe A; Cardoso MC; Gonthier C; Ouchchane L; Schiffmann R; Blanc P; Boespflug-Tanguy O; Fogli A
    PLoS One; 2009 Dec; 4(12):e8318. PubMed ID: 20016818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases.
    Labauge P; Horzinski L; Ayrignac X; Blanc P; Vukusic S; Rodriguez D; Mauguiere F; Peter L; Goizet C; Bouhour F; Denier C; Confavreux C; Obadia M; Blanc F; de Sèze J; Fogli A; Boespflug-Tanguy O
    Brain; 2009 Aug; 132(Pt 8):2161-9. PubMed ID: 19625339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of ten novel mutations in patients with eIF2B-related disorders.
    Ohlenbusch A; Henneke M; Brockmann K; Goerg M; Hanefeld F; Kohlschütter A; Gärtner J
    Hum Mutat; 2005 Apr; 25(4):411. PubMed ID: 15776425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant form of vanishing white matter-like leukoencephalopathy.
    Labauge P; Fogli A; Castelnovo G; Le Bayon A; Horzinski L; Nicoli F; Cozzone P; Pagès M; Briere C; Marty-Double C; Delhaume O; Gelot A; Boespflug-Tanguy O; Rodriguez D
    Ann Neurol; 2005 Oct; 58(4):634-9. PubMed ID: 16047349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Natural history of adult-onset eIF2B-related disorders: a multicentric survey of 24 cases].
    Carra-Dalliere C; Horzinski L; Ayrignac X; Vukusic S; Rodriguez D; Mauguiere F; Peter L; Goizet C; Bouhour F; Denier C; Confavreux C; Obadia M; Blanc F; de Seze J; Sedel F; Guennoc AM; Sartori E; Laplaud D; Antoine JC; Fogli A; Boespflug-Tanguy O; Labauge P
    Rev Neurol (Paris); 2011 Nov; 167(11):802-11. PubMed ID: 21676421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ovarioleukodystrophy.
    Mathis S; Scheper GC; Baumann N; Petit E; Gil R; van der Knaap MS; Neau JP
    Clin Neurol Neurosurg; 2008 Dec; 110(10):1035-7. PubMed ID: 18678442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spectrum of mutations for the diagnosis of vanishing white matter disease.
    Scali O; Di Perri C; Federico A
    Neurol Sci; 2006 Sep; 27(4):271-7. PubMed ID: 16998732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CACH/VWM syndrome and leucodystrophies related to EIF2B mutations].
    Labauge P; Fogli A; Niel F; Rodriguez D; Boespflug-Tanguy O
    Rev Neurol (Paris); 2007 Sep; 163(8-9):793-9. PubMed ID: 17878805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and clinical heterogeneity in eIF2B-related disorder.
    Maletkovic J; Schiffmann R; Gorospe JR; Gordon ES; Mintz M; Hoffman EP; Alper G; Lynch DR; Singhal BS; Harding C; Amartino H; Brown CM; Chan A; Renaud D; Geraghty M; Jensen L; Senbil N; Kadom N; Nazarian J; Yuanjian Feng ; Zuyi Wang ; Hartka T; Morizono H; Vanderver A
    J Child Neurol; 2008 Feb; 23(2):205-15. PubMed ID: 18263758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of genotype on the natural history of eIF2B-related leukodystrophies.
    Fogli A; Schiffmann R; Bertini E; Ughetto S; Combes P; Eymard-Pierre E; Kaneski CR; Pineda M; Troncoso M; Uziel G; Surtees R; Pugin D; Chaunu MP; Rodriguez D; Boespflug-Tanguy O
    Neurology; 2004 May; 62(9):1509-17. PubMed ID: 15136673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus.
    Fogli A; Wong K; Eymard-Pierre E; Wenger J; Bouffard JP; Goldin E; Black DN; Boespflug-Tanguy O; Schiffmann R
    Ann Neurol; 2002 Oct; 52(4):506-10. PubMed ID: 12325082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of ovarioleukodystrophy without eIF2B mutations.
    Gaudiano C; Di Perri C; Scali O; Rufa A; Battisti C; De Stefano N; Federico A
    J Neurol Sci; 2008 May; 268(1-2):183-6. PubMed ID: 18061208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon deletion in the non-catalytic domain of eIF2Bepsilon due to a splice site mutation leads to infantile forms of CACH/VWM with severe decrease of eIF2B GEF activity.
    Horzinski L; Gonthier C; Rodriguez D; Scherer C; Boespflug-Tanguy O; Fogli A
    Ann Hum Genet; 2008 May; 72(Pt 3):410-5. PubMed ID: 18294360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-familial phenotypic heterogeneity in adult onset vanishing white matter disease.
    Damon-Perriere N; Menegon P; Olivier A; Boespflug-Tanguy O; Niel F; Creveaux I; Dousset V; Brochet B; Goizet C
    Clin Neurol Neurosurg; 2008 Dec; 110(10):1068-71. PubMed ID: 18845387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vanishing white matter disease associated with progressive macrocephaly.
    Pineda M; R-Palmero A; Baquero M; O'Callaghan M; Aracil A; van der Knaap M; Scheper GC
    Neuropediatrics; 2008 Feb; 39(1):29-32. PubMed ID: 18504679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of the alpha subunit of human translation initiation factor 2B.
    Hiyama TB; Ito T; Imataka H; Yokoyama S
    J Mol Biol; 2009 Oct; 392(4):937-51. PubMed ID: 19631657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter.
    Leegwater PA; Vermeulen G; Könst AA; Naidu S; Mulders J; Visser A; Kersbergen P; Mobach D; Fonds D; van Berkel CG; Lemmers RJ; Frants RR; Oudejans CB; Schutgens RB; Pronk JC; van der Knaap MS
    Nat Genet; 2001 Dec; 29(4):383-8. PubMed ID: 11704758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptidomics and proteomics studies of transformed lymphocytes from patients mutated for the eukaryotic initiation factor 2B.
    Fogli A; Malinverni C; Thadikkaran L; Combes P; Perret F; Crettaz D; Tissot JD; Boespflug-Tanguy O; Stöcklin R; Bulet P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Aug; 840(1):20-8. PubMed ID: 16824809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.